MentionFox
Home › Executive changes › Lixte Biotechnology Holdings, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Lixte Biotechnology Holdings, Inc. executive changes

Every leadership change Lixte Biotechnology Holdings, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named2
Latest filing2026-07-02

Lixte Biotechnology Holdings, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-02. Between them they name 2 people. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-07-02 · 8-K

Appointed: John Travaglini

On July 1, 2026, the Board appointed John Travaglini to the Board, effective immediately, with a term expiring at the Company's 2026 annual meeting of stockholders.
Filed 2026-06-01 · 8-K

Appointed: Stuart D. Porter, Director, effective 2026-05-29

On May 29, 2026, the Board of Directors (the "Board") of Lixte Biotechnology Holdings, Inc., (the "Company"), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company's 2026 Annual Meeting of Stockholders.
Hiring for a seat like this?

Find people with the same kind of experience as the Director at Lixte Biotechnology Holdings, Inc., with the record behind each one.

Find candidates like Director at Lixte Biotechnology Holdings, Inc.
Selling to Lixte Biotechnology Holdings, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Lixte Biotechnology Holdings, Inc. is in the news or changes leadership.

Get an alert when Lixte Biotechnology Holdings, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Lixte Biotechnology Holdings, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/lixte-biotechnology-holdings
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Lixte Biotechnology Holdings, Inc. (LIXT) executive changes: John Travaglini appointed. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/lixte-biotechnology-holdings